Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization

Annals of Thoracic Surgery

Volumn 68, Issue 4, 1999, Pages 1252-1256

  Kumano, Hiroshi ^a   Suehiro, Shigefumi ^a   Hattori, Koji ^a   Shibata, Toshihiko ^a   Sasaki, Yasuyuki ^a   Hosono, Mitsuharu ^a   Kinoshita, Hiroaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; D DIMER; FIBRINOPEPTIDE A; HEPARIN; PLASMIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; BLOOD CLOTTING DISORDER; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEPARINIZATION; HUMAN; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOSIS;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; ANTITHROMBIN III; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; FIBRINOPEPTIDE A; HEPARIN; HUMANS; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PLASMIN; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE;

EID: 0032695520     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)00697-9     Document Type: Conference Paper

References (20)

1. Bagge L., Lilienberg G., Nyström S.O., Tydén H. Coagulation, fibrinolysis and bleeding after open-heart surgery. Scand J Thorac Cardiovasc Surg. 20:1986;151-160.
2. Hattori K. Clinical effects of standard and heparin-coated circuits on coagulation and fibrinolysis during cardiopulmonary bypass. Jinko Zoki (Jpn J Artif Organs). 25:1996;649-654.
3. Von Segesser L.K., Weiss B.M., Garcia E., von Felten A., Turina M.I. Reduction and elimination of systemic heparinization during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 103:1992;790-799.
4. Øvrum E., Holen E.A.̊, Tangen G., et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin clinical and hemostatic effects . Ann Thorac Surg. 60:1995;365-371.
5. Aldea G.S., Doursounian M., O'Gara P., et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG a prospective, randomized study . Ann Thorac Surg. 62:1996;410-418.
6. Kuitunen A.H., Heikkilä L.J., Salmenperä M.T. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation. Ann Thorac Surg. 63:1997;438-444.
7. Von Segesser L.K., Weiss B.M., Pasic M., Garcia E., Turina M.I. Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg. 58:1994;391-398.
8. Øvrum E., Brosstad F., Holen E.A.̊, Tangen G., Abdelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation. 92:1995;2579-2584.
9. Fosse E., Moen O., Johnson E., et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 58:1994;472-477.
10. Gorman R.C., Ziats N.P., Rao A.K., et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 111:1996;1-12.
11. Amiral J., Walenga J.M., Fareed J. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Semin Thromb Hemost. 10:1984;228-242.
12. Aoki N., Takenaga T., Hasegawa H., et al. Evaluation of the assay for alpha 2 PI and alpha 2 PI-plasmin complex using one step sandwich method (EIA). RinsyoByori. 35:1987;1275-1281.
13. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 59:1988;101-106.
14. Elms M.J., Bunce I.H., Bundesen P.G., et al. Measurement of crosslinked fibrin degradation products an immunoassay using monoclonal antibodies . Thromb Haemost. 50:1983;591-594.
15. Gu Y.J., van Oeveren W., Akkerman C., Boonstra P.W., Huyzen R.J., Wildevuur C.R.H. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:1993;917-922.
16. Tabuchi N., de Haan J., Boonstra P.W., van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:1993;828-833.
17. Minami K., Notohamiprodjo G., Buschler H., Prohaska W., Reichelt W., Körfer R. Alpha-2 plasmin inhibitor-plasmin complex and postoperative blood loss double-blind study with aprotinin in reoperation for myocardial revascularization . J Thorac Cardiovasc Surg. 106:1993;934-936.
18. Steinberg B.M., Grossi E.A., Schwartz D.S., et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg. 60:1995;525-529.
19. Redmond J.M., Gillinov A.M., Stuart R.S., et al. Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg. 56:1993;474-479.
20. Øvrum E., Holen E.A.̊, Tangen G., Ringdal M.A.L. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance. Ann Thorac Surg. 62:1996;1128-1133.